Blocking CXCR4+ CD4+ T cells reprograms Treg-mediated immunosuppression via modulating the Rho-GTPase/NF-κB signaling axis

• Published in: Genome medicine Vol. 17; no. 1; pp. 1 - 23
• Main Authors: Cao, Canhui, Xu, Miaochun, Peng, Ting, Liu, Xiaojie, Lin, Shitong, Xu, Yashi, Chu, Tian, Liu, Shiyi, Wu, Ping, Hu, Bai, Ding, Wencheng, Li, Li, Ma, Ding, Wu, Peng
• Format: Journal Article
• Language: English
• Published: London BioMed Central 04.08.2025; BMC
• Subjects: Animal models; Antagonists; Breast cancer; Cancer immunotherapy; CD4 antigen; CD8 antigen; Cells; Cervical cancer; Chemokines; Clinical trials; CXCR4; CXCR4 protein; Genotype & phenotype; Guanine nucleotide-binding protein; Guanosine triphosphatases; Hospitals; Immunosuppression; Immunotherapy; Laboratory animals; Lymphocytes; Lymphocytes T; Molecular modelling; NF-κB protein; NF-κB2; Organoids; Ovarian cancer; Patients; Penicillin; Phenotypes; Regulatory T (Treg) cells; Review boards; Rho GTPase pathway; Squamous cell carcinoma; Transcriptomics; Tumor microenvironment; Tumors; China

BackgroundWhile clinical trials have shown that CXCR4 antagonists can enhance the efficacy of cancer immunotherapy, the molecular mechanisms by which CXCR4 modulates the tumor microenvironment remain poorly understood. We recently identified CXCR4 as a regulator of exhausted CD8+ T cell phenotypes i...